Page 1 of Clinical Trials for Phosphodiesterase 5 Inhibitors, 520 Total Matches

Show/Hide Clinical Trials Which are Not Seeking New Volunteers

1
Completed
Co-Administering Testosterone With PDE5 Inhibitors in ED Patients Non Responders to PDE5 Inhibitors Alone
Last Updated: August 22, 2008
Condition(s): Erectile Dysfunction; Hypogonadism
2
Completed
Phosphodiesterase-5 Inhibitor in Eisenmenger Syndrome
Last Updated: September 13, 2010
Condition(s): Eisenmenger Syndrome
3
Completed
An Efficacy and Safety Study of Dapoxetine in Men With Premature Ejaculation and Concomitant Erectile Dysfunction Treated With a Phosphodiesterase-5 Inhibitor (ie, Sildenafil, Vardenafil, or Tadalafil)
Last Updated: April 26, 2012
Condition(s): Erectile Dysfunction; Sexual Dysfunction
4
Completed
The Effect of CYP3A Genetic Polymorphism on the Pharmacokinetics of Phosphodiesterase type5 Inhibitors in Male Subjects
Last Updated: October 6, 2008
Condition(s): Pharmacokinetics of Three PDE5Is; Healthy Subjects; Genetic Polymorphic CYP3A5
5
Completed
Study of Ambrisentan and Phosphodiesterase Type-5 Inhibitor (PDE-5i) to Treat Pulmonary Arterial Hypertension
Last Updated: March 20, 2012
Condition(s): Pulmonary Arterial Hypertension
6
Not yet recruiting
Mycophenolate Mofetil, Carnitine and PDE5 Inhibitor, Three Potential Treatments for Resistant Proteinuria Slowing Diabetic Nephropathy Deterioration
Last Updated: March 28, 2012
Condition(s): Diabetic Nephropathy; Chronic Kidney Disease
7
Recruiting
A Study to Determine if There is a Possible Association Between Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) and Phosphodiesterase Type 5 (PDE5) Inhibitors
Last Updated: March 26, 2012
Condition(s): Nonarteritic Anterior Ischemic Optic Neuropathy
8
Withdrawn
A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor
Last Updated: May 10, 2012
Condition(s): Pulmonary Arterial Hypertension
9
Recruiting
PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
Last Updated: May 8, 2012
Condition(s): Anterior Ischemic Optic Neuropathy
10
Completed
Pelvic Angiography in Non-Responders to Phosphodiesterase-5 Inhibitors (PANPI)
Last Updated: March 25, 2008
Condition(s): Erectile Dysfunction
11
Recruiting
Low Intensity Shock Wave Therapy (LI-ESWT) for Erectile Dysfunction in Post Radical Prostatectomy Patients Not Responding to PDE5 Inhibitors (LI-ESWT)
Last Updated: May 23, 2012
Condition(s): Erectile Dysfunction
12
Completed
A Randomised Study of Levitra to Treat Men With Erections Problems and Previously Untreated With Similar Therapy.
Last Updated: June 29, 2009
Condition(s): Erectile Dysfunction
13
Recruiting
Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon
Last Updated: January 28, 2011
Condition(s): Raynaud Phenomenon
14
Recruiting
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Last Updated: May 22, 2012
Condition(s): Optic Neuropathy, Ischemic
15
Completed
Identification of Underlying Conditions in Men Prescribed a PDE5 Inhibitor
Last Updated: April 3, 2012
Condition(s): Erectile Dysfunction; Cardiovascular Diseases; Male Urogenital Diseases
16
Completed
Efficacy and Safety Evaluating Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors
Last Updated: February 2, 2010
Condition(s): Hypogonadism; Erectile Dysfunction
17
Not yet recruiting
Nephroprotective Effects of Carnitine and (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN)
Last Updated: March 24, 2012
Condition(s): Contrast Media Induced Nephropathy
18
Not yet recruiting
Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids.
Last Updated: June 25, 2008
Condition(s): Pulmonary Arterial Hypertension
19
Completed
FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)
Last Updated: January 18, 2012
Condition(s): Pulmonary Hypertension
20
Active, not recruiting
Tezosentan in Patients With Pulmonary Arterial Hypertension
Last Updated: May 26, 2011
Condition(s): Pulmonary Arterial Hypertension

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is: http://clinicaltrialsfeeds.org/clinical-trials/results/?term=Phosphodiesterase+5+Inhibitors

Page 1 of Clinical Trials for Phosphodiesterase 5 Inhibitors, 520 Total Matches

Get the Latest Results via Email or RSS

Subscribe via Web Newsreaders

Browse

Clinical Trials Background

About